Edwards Lifesciences Co. (NYSE:EW) Stock Position Reduced by Andra AP fonden

Andra AP fonden decreased its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 60.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,300 shares of the medical research company's stock after selling 84,400 shares during the period. Andra AP fonden's holdings in Edwards Lifesciences were worth $4,020,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of EW. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the third quarter valued at about $32,000. Avior Wealth Management LLC grew its stake in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $46,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 400 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the sale, the vice president now directly owns 22,588 shares of the company's stock, valued at $1,569,414.24. This represents a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 44,303 shares of company stock worth $3,255,356 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Remove Ads

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded up $0.13 on Wednesday, hitting $68.52. The company had a trading volume of 4,453,470 shares, compared to its average volume of 4,500,150. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market cap of $40.28 billion, a PE ratio of 9.83, a PEG ratio of 4.82 and a beta of 1.12. The business has a 50-day simple moving average of $72.03 and a 200-day simple moving average of $70.35.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research note on Thursday, February 13th. Truist Financial reissued a "hold" rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Bank of America upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Citigroup lifted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.